AR121939A2 - Composición líquida de un conjugado derivado de oxintomodulina de larga duración y procedimiento para prepararla - Google Patents
Composición líquida de un conjugado derivado de oxintomodulina de larga duración y procedimiento para prepararlaInfo
- Publication number
- AR121939A2 AR121939A2 ARP210101118A ARP210101118A AR121939A2 AR 121939 A2 AR121939 A2 AR 121939A2 AR P210101118 A ARP210101118 A AR P210101118A AR P210101118 A ARP210101118 A AR P210101118A AR 121939 A2 AR121939 A2 AR 121939A2
- Authority
- AR
- Argentina
- Prior art keywords
- oxyntomodulin
- long
- liquid composition
- preparing
- conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a una composición líquida libre de albúmina que comprende un conjugado de oxintomodulina de larga duración en el que un péptido de oxintomodulina que comprende un derivado, variante, precursor o fragmento de oxintomodulina está ligado con una región de inmunoglobulina Fc, que puede aumentar la duración de la actividad fisiológica del conjugado de oxintomodulina de larga duración y mantener su estabilidad in vivo durante un período de tiempo prolongado, en comparación con la oxintomodulina nativa, así como un procedimiento para preparar la composición líquida. La composición líquida comprende un tampón, un alcohol de azúcar y un tensioactivo no iónico y no contiene una albúmina sérica humana ni factores que son potencialmente nocivos para el cuerpo humano y, así, no es susceptible de una infección vírica. Además, el conjugado de oxintomodulina de la invención comprende oxintomodulina ligada con una región de inmunoglobulina Fc y, así, tiene un gran peso molecular, prolongada actividad fisiológica y excelente estabilidad en almacenamiento, en comparación con la oxintomodulina nativa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120124725 | 2012-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121939A2 true AR121939A2 (es) | 2022-07-27 |
Family
ID=50684883
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104071A AR093387A1 (es) | 2012-11-06 | 2013-11-06 | Formulacion liquida de un conjugado de proteina que comprende oxintomodulina y un fragmento de inmunoglobulina |
ARP210101118A AR121939A2 (es) | 2012-11-06 | 2021-04-26 | Composición líquida de un conjugado derivado de oxintomodulina de larga duración y procedimiento para prepararla |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104071A AR093387A1 (es) | 2012-11-06 | 2013-11-06 | Formulacion liquida de un conjugado de proteina que comprende oxintomodulina y un fragmento de inmunoglobulina |
Country Status (27)
Country | Link |
---|---|
US (3) | US9724420B2 (es) |
EP (2) | EP3610856B1 (es) |
JP (2) | JP6363612B2 (es) |
KR (2) | KR102311517B1 (es) |
CN (1) | CN104884045B (es) |
AR (2) | AR093387A1 (es) |
AU (3) | AU2013342321B2 (es) |
BR (1) | BR112015010235B1 (es) |
CA (1) | CA2890324C (es) |
CL (1) | CL2015001206A1 (es) |
DK (1) | DK2916819T3 (es) |
EA (3) | EA031852B1 (es) |
ES (1) | ES2748158T3 (es) |
HK (1) | HK1210044A1 (es) |
IL (2) | IL238626B (es) |
MX (2) | MX2015005698A (es) |
MY (2) | MY197849A (es) |
NZ (3) | NZ708103A (es) |
PE (1) | PE20151421A1 (es) |
PH (2) | PH12018501454A1 (es) |
PL (1) | PL2916819T3 (es) |
PT (1) | PT2916819T (es) |
SG (2) | SG10201602801YA (es) |
TW (3) | TWI602583B (es) |
UA (2) | UA126651C2 (es) |
WO (1) | WO2014073842A1 (es) |
ZA (1) | ZA201503998B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103732618B (zh) | 2011-06-10 | 2018-10-09 | 韩美科学株式会社 | 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物 |
SI2721062T1 (sl) | 2011-06-17 | 2019-03-29 | Hanmi Science Co., Ltd. | Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
MY197849A (en) | 2012-11-06 | 2023-07-20 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
EP2934568B1 (en) | 2012-12-21 | 2017-10-18 | Sanofi | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3098235A4 (en) | 2014-01-20 | 2017-10-18 | Hanmi Pharm. Co., Ltd. | Long-acting insulin and use thereof |
SG11201608120TA (en) * | 2014-03-31 | 2016-11-29 | Hanmi Pharm Ind Co Ltd | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
CN105435221B (zh) * | 2014-09-22 | 2021-09-28 | 正大天晴药业集团股份有限公司 | 一种针对血管内皮生长因子的人源化抗体的药物组合物 |
TW201639878A (zh) | 2014-12-30 | 2016-11-16 | 韓美藥品股份有限公司 | 具有改善之安定性的升糖素衍生物 |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
PT3322437T (pt) | 2015-06-30 | 2024-03-20 | Hanmi Pharmaceutical Co Ltd | Derivado de glucagon e composição que compreende um conjugado de ação prolongada do mesmo |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
AU2015416589B2 (en) * | 2015-12-10 | 2021-04-01 | Menicon Co., Ltd. | Peptide composition |
CN116063453A (zh) | 2015-12-31 | 2023-05-05 | 韩美药品株式会社 | 胰高血糖素/glp-1/gip受体三重激动剂 |
MX2019000019A (es) * | 2016-06-29 | 2019-05-06 | Hanmi Pharm Ind Co Ltd | Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo. |
EP3517544A4 (en) | 2016-09-23 | 2020-06-03 | Hanmi Pharm. Co., Ltd. | INSULIN ANALOG HAVING REDUCED INSULIN RECEPTOR BINDING FORCE AND USE THEREOF |
JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
CN108299553B (zh) * | 2017-01-13 | 2021-07-16 | 博瑞生物医药(苏州)股份有限公司 | 胃泌酸调节素修饰物 |
MX2019011297A (es) | 2017-03-23 | 2019-11-12 | Hanmi Pharm Ind Co Ltd | Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo. |
AU2019308089A1 (en) | 2018-07-19 | 2021-01-21 | D&D Pharmatech Inc. | Pharmaceutical composition comprising polypeptide |
US20200262887A1 (en) | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
US20220242913A1 (en) * | 2019-02-15 | 2022-08-04 | Hanmi Fine Chemical Co., Ltd. | Novel intermediate used for biologically active polypeptide and method for preparing same |
KR20210144608A (ko) | 2020-05-22 | 2021-11-30 | 한미약품 주식회사 | 액상 제제 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
CN1264569C (zh) | 1998-03-06 | 2006-07-19 | 中外制药株式会社 | 无蛋白制剂 |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7217845B2 (en) | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
WO2005035761A1 (en) | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
ES2438098T3 (es) | 2003-11-13 | 2014-01-15 | Hanmi Science Co., Ltd. | Composición farmacéutica que comprende un Fc de inmunoglobulina como vehículo |
US20090238838A1 (en) | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
JP5185624B2 (ja) | 2004-12-02 | 2013-04-17 | ドマンティス リミテッド | 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体 |
EP2390264A1 (en) | 2005-02-11 | 2011-11-30 | Amylin Pharmaceuticals Inc. | GIP analog and hybrid polypeptides with selectable propperties |
WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
JP2008543816A (ja) | 2005-06-13 | 2008-12-04 | インペリアル イノベーションズ リミテッド | 新規化合物および該化合物が摂食行動に及ぼす効果 |
GB0511986D0 (en) | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
US20090297496A1 (en) | 2005-09-08 | 2009-12-03 | Childrens Hospital Medical Center | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases |
US7928058B2 (en) | 2006-02-22 | 2011-04-19 | Merck Sharp & Dohme Corp. | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition |
CA2654055A1 (en) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
GB0624868D0 (en) | 2006-12-13 | 2007-01-24 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
CN101730523A (zh) | 2007-07-10 | 2010-06-09 | 伊莱利利公司 | GLP-1-Fc融合蛋白质制剂 |
KR101545181B1 (ko) | 2007-07-27 | 2015-08-21 | 바이엘 크롭사이언스 아게 | 삼원 활성 화합물의 배합물 |
WO2009043478A2 (en) | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009058734A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
JP2011503000A (ja) | 2007-11-02 | 2011-01-27 | セントコア・オーソ・バイオテツク・インコーポレーテツド | 半合成GLP−1ペプチド−Fc融合コンストラクト、その方法及び使用 |
JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
EP2307037A4 (en) | 2008-06-17 | 2011-08-03 | Univ Indiana Res & Tech Corp | GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS |
MX2010013454A (es) | 2008-06-17 | 2011-01-21 | Tion Indiana University Res And Technology Corpora | Co-agonistas de receptor de glucagon/glp-1. |
WO2010013012A2 (en) | 2008-08-01 | 2010-02-04 | Lund University Bioscience Ab | Novel polypeptides and uses thereof |
US20110171312A1 (en) | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
US8680263B2 (en) | 2008-09-19 | 2014-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
CA2747155A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
EP2376097A4 (en) | 2008-12-19 | 2012-10-03 | Univ Indiana Res & Tech Corp | AMID-BASED PEPTIDE PRODRUGS OF THE GLUCAGON SUPERFAMILY |
WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
BRPI1013626B8 (pt) | 2009-03-20 | 2021-05-25 | Hanmi Holdings Co Ltd | método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico |
EP2432488A4 (en) | 2009-03-20 | 2014-01-08 | Amgen Inc | SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS |
AU2010260058B2 (en) | 2009-06-16 | 2015-09-24 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
SI2454282T1 (sl) | 2009-07-13 | 2015-06-30 | Zealand Pharma A/S | Acilirani glukagonski analogi |
US20120294855A1 (en) | 2009-11-03 | 2012-11-22 | Eli Lilly & Company | Glp-1 receptor agonist compounds for obstructive sleep apnea |
US20120269830A1 (en) | 2009-12-07 | 2012-10-25 | Lawrence Horowitz | Conjugates with improved pharmacokinetic properties |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
JP2013518115A (ja) | 2010-01-27 | 2013-05-20 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐gipアゴニスト複合体及び組成物 |
EP2552951A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
JP6050746B2 (ja) | 2010-05-13 | 2016-12-21 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Gタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド |
WO2011163012A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
KR101314865B1 (ko) * | 2010-07-06 | 2013-10-04 | 김덕중 | 모바일 환경에서 tv 화면과 연동하는 증강 현실을 제공하는 방법, 이를 위한 부가 서비스 서버 및 방송 시스템 |
KR101337797B1 (ko) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
JP5282146B2 (ja) | 2010-09-06 | 2013-09-04 | パナソニック株式会社 | 表示装置及びその制御方法 |
CN101974077A (zh) | 2010-09-15 | 2011-02-16 | 南京瑞年天平医药科技有限公司 | 一种新颖的多肽化合物 |
KR101767570B1 (ko) * | 2010-10-26 | 2017-08-14 | 한미사이언스 주식회사 | 항 비만 펩타이드의 지속형 결합체 |
KR101303388B1 (ko) | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
CN102010473A (zh) * | 2010-11-10 | 2011-04-13 | 曹鹏 | 重组胃泌酸调节素融合蛋白及其制备和应用 |
NZ611878A (en) | 2010-12-22 | 2015-02-27 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
EP2492749A1 (en) | 2011-02-28 | 2012-08-29 | Rohm and Haas Electronic Materials LLC | Photoresist compositions and methods of forming photolithographic patterns |
KR101161526B1 (ko) | 2011-05-16 | 2012-07-02 | 숭실대학교산학협력단 | 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법 |
CN103732618B (zh) | 2011-06-10 | 2018-10-09 | 韩美科学株式会社 | 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物 |
SI2721062T1 (sl) * | 2011-06-17 | 2019-03-29 | Hanmi Science Co., Ltd. | Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega |
CA2839867A1 (en) | 2011-06-22 | 2012-12-27 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
KR101665009B1 (ko) | 2012-03-09 | 2016-10-11 | 한미사이언스 주식회사 | 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 |
BR112014025951A2 (pt) | 2012-04-19 | 2017-07-11 | Opko Biologics Ltd | variantes de oxintomodulina de longa ação e métodos de produção do mesmo |
US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
KR101373563B1 (ko) | 2012-07-25 | 2014-03-12 | 전북대학교산학협력단 | Tof-mra를 이용한 혈류특성 및 mr-신호강도구배(전단율) 유도방법 |
WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
MY197849A (en) * | 2012-11-06 | 2023-07-20 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
JP6137046B2 (ja) | 2014-05-09 | 2017-05-31 | 信越化学工業株式会社 | 単量体、高分子化合物、レジスト材料及びパターン形成方法 |
TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
WO2019171352A2 (en) | 2018-03-08 | 2019-09-12 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
-
2013
- 2013-11-06 MY MYPI2018703890A patent/MY197849A/en unknown
- 2013-11-06 NZ NZ708103A patent/NZ708103A/en unknown
- 2013-11-06 JP JP2015540613A patent/JP6363612B2/ja active Active
- 2013-11-06 MX MX2015005698A patent/MX2015005698A/es active IP Right Grant
- 2013-11-06 EA EA201590758A patent/EA031852B1/ru not_active IP Right Cessation
- 2013-11-06 ES ES13853118T patent/ES2748158T3/es active Active
- 2013-11-06 MY MYPI2015001169A patent/MY168536A/en unknown
- 2013-11-06 US US14/440,422 patent/US9724420B2/en active Active
- 2013-11-06 UA UAA201711010A patent/UA126651C2/uk unknown
- 2013-11-06 SG SG10201602801YA patent/SG10201602801YA/en unknown
- 2013-11-06 PE PE2015000593A patent/PE20151421A1/es unknown
- 2013-11-06 UA UAA201504473A patent/UA116364C2/uk unknown
- 2013-11-06 PH PH12018501454A patent/PH12018501454A1/en unknown
- 2013-11-06 SG SG11201503370WA patent/SG11201503370WA/en unknown
- 2013-11-06 EP EP19180160.4A patent/EP3610856B1/en active Active
- 2013-11-06 EP EP13853118.1A patent/EP2916819B1/en active Active
- 2013-11-06 PT PT138531181T patent/PT2916819T/pt unknown
- 2013-11-06 TW TW102140249A patent/TWI602583B/zh active
- 2013-11-06 EA EA201791143A patent/EA034499B1/ru not_active IP Right Cessation
- 2013-11-06 BR BR112015010235-2A patent/BR112015010235B1/pt active IP Right Grant
- 2013-11-06 EA EA201992760A patent/EA039082B1/ru unknown
- 2013-11-06 AU AU2013342321A patent/AU2013342321B2/en active Active
- 2013-11-06 TW TW106126398A patent/TWI652071B/zh active
- 2013-11-06 NZ NZ731658A patent/NZ731658A/en unknown
- 2013-11-06 CN CN201380069534.3A patent/CN104884045B/zh active Active
- 2013-11-06 WO PCT/KR2013/009986 patent/WO2014073842A1/en active Application Filing
- 2013-11-06 NZ NZ73906313A patent/NZ739063A/en unknown
- 2013-11-06 PL PL13853118T patent/PL2916819T3/pl unknown
- 2013-11-06 AR ARP130104071A patent/AR093387A1/es not_active Application Discontinuation
- 2013-11-06 KR KR1020130134412A patent/KR102311517B1/ko active IP Right Grant
- 2013-11-06 DK DK13853118.1T patent/DK2916819T3/da active
- 2013-11-06 TW TW108101828A patent/TWI816739B/zh active
- 2013-11-06 CA CA2890324A patent/CA2890324C/en active Active
-
2015
- 2015-05-04 IL IL238626A patent/IL238626B/en active IP Right Grant
- 2015-05-06 MX MX2020004114A patent/MX2020004114A/es unknown
- 2015-05-06 PH PH12015501008A patent/PH12015501008A1/en unknown
- 2015-05-06 CL CL2015001206A patent/CL2015001206A1/es unknown
- 2015-06-04 ZA ZA2015/03998A patent/ZA201503998B/en unknown
- 2015-11-05 HK HK15110919.0A patent/HK1210044A1/xx unknown
-
2017
- 2017-06-29 US US15/637,583 patent/US10279041B2/en active Active
- 2017-12-18 AU AU2017279583A patent/AU2017279583B2/en active Active
-
2018
- 2018-06-28 JP JP2018123264A patent/JP6694013B2/ja active Active
-
2019
- 2019-01-21 IL IL26436019A patent/IL264360B/en active IP Right Grant
- 2019-03-18 US US16/356,319 patent/US11071785B2/en active Active
-
2020
- 2020-01-29 AU AU2020200626A patent/AU2020200626B2/en active Active
-
2021
- 2021-04-26 AR ARP210101118A patent/AR121939A2/es unknown
- 2021-09-30 KR KR1020210129977A patent/KR102434280B1/ko active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR121939A2 (es) | Composición líquida de un conjugado derivado de oxintomodulina de larga duración y procedimiento para prepararla | |
AR082223A1 (es) | Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodo | |
CY1122146T1 (el) | Μια υγρη μορφοποιηση μακρας διαρκειας δρασης και ινσουλινοτροπο πεπτιδιο | |
PE20151409A1 (es) | Analogo de insulina novedoso y su uso | |
EA201490070A1 (ru) | Коантагонисты глюкагонового рецептора/glp-1-рецептора | |
GT201400279A (es) | Jeringa | |
NZ628398A (en) | Stable preservative-free mydriatic and anti-inflammatory solutions for injection | |
NI201200013A (es) | Composición de insulina de acción prolongada | |
PE20140795A1 (es) | Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada | |
BR112014032990A2 (pt) | seringa | |
PE20240825A1 (es) | Anticuerpos anti-c5 y metodos de uso | |
PE20142168A1 (es) | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas | |
AR095451A1 (es) | Formulación de anticuerpos | |
EA201391136A1 (ru) | Лиофилизированные составы | |
PH12015502645B1 (en) | Igg4 fc fragment comprising modified hinge region | |
TW201129387A (en) | Liquid formulation for long-acting G-CSF conjugate | |
AR102096A1 (es) | Proceso para elaborar acetato de glatiramer | |
CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares | |
AR090583A1 (es) | Formulacion liquida de conjugados de la hormona de crecimiento humana de accion prolongada, altamente concentrada | |
MX2018013177A (es) | Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas. | |
AR096092A1 (es) | ANTICUERPOS ANTI-IGF-1R CON ABOLICIÓN DE LA UNIÓN AL FcRn Y SU UTILIZACIÓN EN EL TRATAMIENTO DE ENFERMEDADES OCULARES VASCULARES | |
TH162100B (th) | สูตรตำรับรูปแบบของเหลวของโปรตีนคอนจูเกต (Protein Conjugate) ที่ประกอบด้วยออกซินโทโมดูลิน (Oxyntomodulin) และชิ้นส่วนของอิมมูโนโกลบูลิน (mmunoglobulin fragment) | |
TH162100A (th) | สูตรตำรับรูปแบบของเหลวของโปรตีนคอนจูเกต (Protein Conjugate) ที่ประกอบด้วยออกซินโทโมดูลิน (Oxyntomodulin) และชิ้นส่วนของอิมมูโนโกลบูลิน (mmunoglobulin fragment) | |
DOP2014000302A (es) | Solucion de acetaminofen supersaturada inyectable para la administracion por la espina dorsal | |
EA201300197A1 (ru) | Пептиды с цитопротекторной активностью и фармацевтическая композиция |